JPRN-UMIN000022431已完成未知
Single-arm phase II study of aggressive local therapy in combination with systemic chemotherapy for stageIV non-small cell carcinoma not harboring EGFR mutation and ALK fusion gene with oligometastases - CURE-OLIGO
Thoracic Oncology Research Group0 个研究点目标入组 19 人开始时间: 2016年6月1日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 19
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 74years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with pleural effusion, cardiac effusion, pleural dissemination, peritoneal dissemination, and/or ascites 2) Patients who are ineligible to treat with thoracic radiotherapy due to interstitial pneumonitis and/or severe COPD
研究者
相似试验
已完成
不适用
ocal HER-O: A study of local therapy for the treatment of brain metastases from Human Epidermal Growth Factor Receptor Type 2 (HER2) positive breast cancer.Metastatic HER2 positive breast cancer - brain metastasesCancer - BreastCancer - BrainACTRN12616001265460Trans Tasman Radiation Oncology Research Group (TROG)25
招募中
2 期
Preceding local therapy to STRIDE for pretreated patientsHepatocellular carcinomaJPRN-jRCT1041230013Yamashita Tatsuya36
进行中（未招募）
1 期
Clinical trial to investigate the efficacy of treatment combination with gemcitabine and pazopanib in patients with inoperable locally advanced or metastatic gallbladder and bile duct cancerInoperable locally advanced or metastatic cancer of the biliary tree (cholangiocarcinoma and gallbladder carcinoma)MedDRA version: 14.1Level: LLTClassification code 10017620Term: Gallbladder carcinomaSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10004655Term: Biliary carcinomaSystem Organ Class: 100000004864EUCTR2012-001705-24-GRHellenic Cooperative Oncology Group46
Unknown
2 期
Chemo- radiotherapy of cancer of cheek with Tomotherapy .CTRI/2010/091/002920Tata Memorial Hospital55
招募中
1 期
A clinical study to test the effect of niraparib and immunotherapy, for patients with small cell lung cancer (SCLC) that is positive for SLFN11.Extensive-disease small cell lung cancer and high SLFN11-expressionMedDRA version: 21.1Level: PTClassification code: 10041067Term: Small cell lung cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10041068Term: Small cell lung cancer extensive stage Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10025044Term: Lung cancer Class: 10029104CTIS2022-502092-33-00ETOP IBCSG Partners Foundation44